Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins

Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral
                             Delivery of Proteins

PR Newswire

JERUSALEM, April 3, 2013

JERUSALEM, April 3, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that it has received
approval for a key patent by the Japanese Patent Office. The patent, titled
"Methods and Compositions for Oral Administrations of Proteins," covers a core
concept of the company's technology. The patent has also been approved in
Israel and Australia. Oramed's portfolio now consists of seven issued patents
and 28 patents pending.

According to a report by the European Federation of Pharmaceutical Industries
and Associations, Japan constitutes 12% of the global sales of new medicines
launched in the period from 2006 to 2010.

Nadav Kidron, CEO of Oramed, commented, "We are very excited to add the
Japanese patent to our international portfolio. The Japanese patent approval
represents a great success in further establishing the global standing of
Oramed's innovative oral delivery technology."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under U.S. IND, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

The company's fact sheet can be viewedhere.

SafeHarborfor Forward-Looking Statements: This press release contains
forward-looking statements. For example, we are using forward-looking
statements when we discuss our approaching of phase 2 clinical trials. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company and Investor Relations Contact:
Aviva Sherman
USA: +1-646-240-4193
Int'l:+972-2-566-0001
+972-54-792-4438
E-mail: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.